Majer Weronika, Kluzek Katarzyna, Bluyssen Hans, Wesoły Joanna
1. Laboratory of High Throughput Technologies, Institute of Molecular Biology and Biotechnology, Faculty of Biology, University of Adam Mickiewicz, Umultowska 89, 61-614 Poznan, Poland, Tel. +4861 829 5832, Fax. +4861 829 5949.
2. Department of Human Molecular Genetics, Institute of Molecular Biology and Biotechnology, Faculty of Biology, University of Adam Mickiewicz, Umultowska 89, 64-614 Poznan, Tel. +4861 829 5832.
J Cancer. 2015 Sep 5;6(11):1105-13. doi: 10.7150/jca.12145. eCollection 2015.
The early diagnosis and monitoring of clear-cell Renal Cell Carcinoma (ccRCC), which is the most common renal malignancy, remains challenging. The late diagnosis and lack of tools that can be used to assess the progression of the disease and metastasis significantly influence the chance of survival of ccRCC patients. Molecular biomarkers have been shown to aid the diagnosis and disease monitoring for other cancers, but such markers are not currently available for ccRCC. Recently, plasma and serum circulating nucleic acids, nucleic acids present in urine, and plasma and urine proteins gained interest in the field of cancer biomarker discovery. Here, we describe the applicability of plasma and urine nucleic acids as cancer biomarkers with a particular focus on DNA, small RNA, and protein markers for ccRCC.
透明细胞肾细胞癌（ccRCC）是最常见的肾脏恶性肿瘤，其早期诊断和监测仍然具有挑战性。疾病的晚期诊断以及缺乏可用于评估疾病进展和转移的工具，显著影响了ccRCC患者的生存机会。分子生物标志物已被证明有助于其他癌症的诊断和疾病监测，但目前ccRCC尚无此类标志物。最近，血浆和血清中的循环核酸、尿液中的核酸以及血浆和尿液中的蛋白质在癌症生物标志物发现领域引起了关注。在此，我们描述了血浆和尿液核酸作为癌症生物标志物的适用性，特别关注ccRCC的DNA、小RNA和蛋白质标志物。
